Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study.
BACKGROUND: The viral pandemic coronavirus disease 2019 (COVID-19) has disrupted cancer patient management around the world. Most reported data relate to incidence, risk factors, and outcome of severe COVID-19. The safety of systemic anti-cancer therapy in oncology patients with non-severe COVID-19 is an important matter in daily practice. METHODS: ONCOSARS-1 was a single-center, academic observational study. Adult patients with solid tumors treated in the oncology day unit with systemic anti-cancer therapy during the initial phase of the COVID-19 pandemic in Belgium were prospectively include... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2021 |
Verlag/Hrsg.: |
BioMed Central
|
Schlagwörter: | Aged / Ambulatory Care / Belgium / COVID-19 / Cancer Care Facilities / Cohort Studies / Female / Health Personnel / Humans / Male / Middle Aged / Neoplasms / Risk Factors / SARS-CoV-2 / Ambulatory / Non-severe COVID-19 / Safety / Systemic anti-cancer treatment |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26980224 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2078.1/253283 |